Novacyt SA - Surrey-based biotechnology group focused on clinical diagnostics - Launches two new CE marked PCR tests. One test, Winterplex, can diagnose Covid-19, types of influenza and respiratory syncytial virus, which can cause infections of the respiratory tract. Another test, named Escapeplex, can diagnose four Covid-19 variants. However, company notes an already announced delay to its PathFlow lateral flow test is down to increased demand for self-test approvals, leading to regulatory backlog. "The notified body has communicated a delay of up to six months, therefore, the company is also evaluating other approved options for a Covid-19 self-LFT," Novacyt says.
Current stock price: 277.10 pence, down 3.3% on Thursday
Year-to-date change: down 68%
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.